Han Chu Lee
About
Han Chu Lee is a scholar working on Hepatology, Epidemiology and Surgery.
According to data from OpenAlex, Han Chu Lee has authored 277 papers receiving a total of 10.5k indexed citations (citations by other indexed papers that have themselves been cited), including 219 papers in Hepatology, 162 papers in Epidemiology and 53 papers in Surgery. Recurrent topics in Han Chu Lee's work include Liver Disease Diagnosis and Treatment (121 papers), Hepatocellular Carcinoma Treatment and Prognosis (120 papers) and Hepatitis B Virus Studies (95 papers). Han Chu Lee is often cited by papers focused on Liver Disease Diagnosis and Treatment (121 papers), Hepatocellular Carcinoma Treatment and Prognosis (120 papers) and Hepatitis B Virus Studies (95 papers). Han Chu Lee collaborates with scholars based in South Korea, United States and Japan. Han Chu Lee's co-authors include Young‐Suk Lim, Kang Mo Kim, Yung Sang Lee, Ju Hyun Shim, Dong Jin Suh, Jihyun An, Young–Hwa Chung, Young‐Hwa Chung, Danbi Lee and Sung‐Gyu Lee and has published in prestigious journals such as Circulation, Nature Medicine and Journal of Clinical Oncology.
In The Last Decade
Han Chu Lee
267 papers receiving 10.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Han Chu Lee South Korea | 52 | 7.7k | 5.6k | 1.9k | 1.4k | 1.3k | 277 | 10.5k | ||
| Young‐Suk Lim South Korea | 57 | 8.5k 1.1× | 6.9k 1.2× | 1.9k 1.0× | 1.4k 0.9× | 840 0.6× | 336 | 11.0k | ||
| Olivier Rosmorduc France | 43 | 4.6k 0.6× | 3.0k 0.5× | 2.3k 1.2× | 2.4k 1.7× | 1.2k 0.9× | 129 | 8.0k | ||
| Manel Solé Spain | 38 | 4.0k 0.5× | 3.1k 0.5× | 1.8k 0.9× | 1.1k 0.8× | 433 0.3× | 135 | 7.1k | ||
| Iwao Ikai Japan | 54 | 6.6k 0.9× | 3.5k 0.6× | 4.1k 2.2× | 2.1k 1.5× | 678 0.5× | 221 | 10.3k | ||
| Adam C. Yopp United States | 51 | 4.0k 0.5× | 3.8k 0.7× | 2.3k 1.2× | 3.6k 2.5× | 502 0.4× | 217 | 10.0k | ||
| Won Young Tak South Korea | 37 | 3.4k 0.4× | 2.3k 0.4× | 1.4k 0.7× | 901 0.6× | 916 0.7× | 201 | 5.9k | ||
| Dominique Franco France | 48 | 5.1k 0.7× | 2.9k 0.5× | 3.6k 1.9× | 2.9k 2.0× | 511 0.4× | 185 | 9.9k | ||
| Ronnie T. P. Poon Hong Kong | 54 | 4.5k 0.6× | 2.3k 0.4× | 3.0k 1.6× | 3.5k 2.5× | 727 0.5× | 137 | 10.2k | ||
| Tan To Cheung Hong Kong | 43 | 4.3k 0.6× | 2.3k 0.4× | 2.3k 1.2× | 1.6k 1.1× | 454 0.3× | 252 | 6.8k | ||
| R. Vilana Spain | 39 | 6.7k 0.9× | 4.5k 0.8× | 1.9k 1.0× | 1.1k 0.7× | 496 0.4× | 92 | 8.2k |
Countries citing papers authored by Han Chu Lee
Since
Specialization
Citations
This map shows the geographic impact of Han Chu Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Han Chu Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Han Chu Lee more than expected).
Fields of papers citing papers by Han Chu Lee
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Han Chu Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Han Chu Lee. The network helps show where Han Chu Lee may publish in the future.
Co-authorship network of co-authors of Han Chu Lee
This figure shows the co-authorship network connecting the top 25 collaborators of Han Chu Lee. A scholar is included among the top collaborators of Han Chu Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Han Chu Lee. Han Chu Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Chung, Sung Won, Jin Sun Kim, Won‐Mook Choi, et al.. (2025). Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma. Clinical Cancer Research. 31(10). 2046–2055.
2.
Jung, Jinhong, Jonggi Choi, Jin Hyoung Kim, et al.. (2025). Combined Transarterial Chemoembolization and External Beam Radiotherapy for Identifying Surgical Candidates for Hepatocellular Carcinoma with Macroscopic Vascular Invasion: A Propensity Score–Weighted Analysis. Cancer Research and Treatment. 58(1). 275–283.
3.
Yang, Jiwon, Won‐Mook Choi, Ju Hyun Shim, et al.. (2024). Revisiting the steatosis‐associated fibrosis estimator score in young Asian subjects with steatotic liver disease and consideration for population variability. Journal of Gastroenterology and Hepatology. 39(10). 2112–2119.
4.
Chung, Sung Won, Ye‐Jee Kim, Jonggi Choi, et al.. (2024). Risk of Extrahepatic Malignancies in Patients With Autoimmune Hepatitis: A Nationwide Cohort Study. The American Journal of Gastroenterology. 120(10). 2302–2311.
5.
Kim, Hyung‐Don, Ho Yeong Lim, Baek‐Yeol Ryoo, et al.. (2024). Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial. Nature Medicine. 30(3). 699–707.
6.
Choi, Won‐Mook, Ju Hyun Shim, Danbi Lee, et al.. (2023). Subclassification of advanced-stage hepatocellular carcinoma with macrovascular invasion: combined transarterial chemoembolization and radiotherapy as an alternative first-line treatment. SHILAP Revista de lepidopterología. 23(1). 177–188.
7.
Kaseb, Ahmed S., Minshan Chen, Pierce K. H. Chow, et al.. (2023). IMbrave050: Efficacy, safety and patient-reported outcomes (PROs) for adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in hepatocellular carcinoma (HCC) patients at high risk of disease recurrence after resection or ablation. Journal of Hepatology. 78. S9–S10.
8.
Choi, Won‐Mook, Ju Hyun Shim, Danbi Lee, et al.. (2022). Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment‐naïve chronic hepatitis B. Liver International. 42(7). 1517–1527.
9.
Jung, Jinhong, Ji Hyeon Joo, So Yeon Kim, et al.. (2021). Radiologic Response as a Prognostic Factor in Advanced Hepatocellular Carcinoma with Macroscopic Vascular Invasion after Transarterial Chemoembolization and Radiotherapy. Liver Cancer. 11(2). 152–161.
10.
An, Jihyun, Deokhoon Kim, Ji‐Hyun Song, et al.. (2021). Comprehensive characterization of viral integrations and genomic aberrations in HBV‐infected intrahepatic cholangiocarcinomas. Hepatology. 75(4). 997–1011.
11.
Park, Soree, Eun‐Sook Park, Ja Eun Koo, et al.. (2020). Entecavir‐resistant hepatitis B virus decreases surface antigenicity: A full genome and functional characterization. Liver International. 40(7). 1564–1577.
12.
Choi, Jonggi, Danbi Lee, Ju Hyun Shim, et al.. (2020). Evaluation of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma. PLoS ONE. 15(3). e0229696–e0229696.
13.
Choi, Won‐Mook, Jonggi Choi, Danbi Lee, et al.. (2020). Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma. Hepatology Communications. 4(7). 1073–1086.
14.
Kim, Jin Hyoung, Jin Hyoung Kim, Ju Hyun Shim, et al.. (2017). New intermediate‐stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization. Liver International. 37(12). 1861–1868.
15.
Yu, Jeong Il, Jae Won Park, Hee Chul Park, et al.. (2016). Clinical impact of combined transarterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: An external validation study. Radiotherapy and Oncology. 118(2). 408–415.
16.
Kim, Gi‐Ae, Young‐Suk Lim, Jihyun An, et al.. (2014). HBSAG Seroclearance after Nucleoside Analogue Therapy in Patients with Chronic Hepatitis B. 43–43.
17.
An, Jihyun, Young‐Suk Lim, Gi‐Ae Kim, et al.. (2014). Tenofovir Monotherapy in Chronic Hepatitis B Patients with Genotypic Resistance to Previous Antiviral Therapy. 46–46.
18.
Shim, Ju Hyun, Han Chu Lee, Seungbong Han, et al.. (2012). Hepatocyte nuclear factor 1β is a novel prognostic marker independent of the milan criteria in transplantable hepatocellular carcinoma: A retrospective analysis based on tissue microarrays. Liver Transplantation. 19(3). 336–345.
19.
Song, Moon Hee, Young‐Suk Lim, Jin‐Ho Choi, et al.. (2005). The etiology of acute viral hepatitis for the last 3 years. The Korean Journal of Internal Medicine. 68(3). 256–260.
20.
Kim, In‐Sook, Young‐Suk Lim, Hyun‐Ki Yoon, et al.. (2005). The effect of preoperative transarterial chemoembolization on the patient's outcome in resectable hepatocellular carcinoma. The Korean Journal of Internal Medicine. 69(6). 614–621.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Young‐Suk Lim Breakdown of academic impact, for papers by Olivier Rosmorduc Breakdown of academic impact, for papers by Manel Solé Breakdown of academic impact, for papers by Iwao Ikai Breakdown of academic impact, for papers by Adam C. Yopp Breakdown of academic impact, for papers by Won Young Tak Breakdown of academic impact, for papers by Dominique Franco Breakdown of academic impact, for papers by Ronnie T. P. Poon Breakdown of academic impact, for papers by Tan To Cheung Breakdown of academic impact, for papers by R. Vilana